A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

O. G. Best, A. C. Gardiner, A. Majid, R. Walewska, B. Austen, A. Skowronska, R. Ibbotson, T. Stankovic, M. J. Dyer, D. G. Oscier

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)
Original languageEnglish
Pages (from-to)1456-1459
Number of pages4
Issue number7
Publication statusPublished - Jul 2008
Externally publishedYes

Bibliographical note

1476-5551 Best, O G Gardiner, A C Majid, A Walewska, R Austen, B Skowronska, A Ibbotson, R Stankovic, T Dyer, M J S Oscier, D G MC_U132670597/Medical Research Council/United Kingdom Letter England Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17.


  • Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Ataxia Telangiectasia Mutated Proteins Cell Cycle Proteins/*genetics Cyclin-Dependent Kinase Inhibitor p21/genetics DNA-Binding Proteins/*genetics Etoposide/*administration & dosage *Genes, p53 Humans Imidazoles/*administration & dosage Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics *Mutation Piperazines/*administration & dosage Protein-Serine-Threonine Kinases/*genetics Tumor Suppressor Proteins/*genetics

Cite this